| abstract |
1,2,4] triazolo [l, 5-a] pyridine compounds having the formula represented by formula I: Such compounds may be prepared as pharmaceutical compositions and may be administered to mammals, including humans, in a non-limiting manner, for example, diseases involving cartilage degradation, bone and / or joint degradation, such as osteoarthritis; Inflammatory bowel disease, endotoxin-mediated inflammatory bowel disease, and / or inflammatory bowel disease and / or inflammatory or immune-mediated diseases such as Crohn's disease, rheumatoid arthritis, psoriasis, allergic airways diseases (e.g. asthma, rhinitis), childhood idiopathic arthritis, (E.g. chronic post-operative complications or chronic endotoxin causing chronic heart failure), diseases accompanied by disorders of cartilage conversion (e. G., Diseases involving catabolic stimulation of cartilage cells ), Congenital cartilaginous tumors, diseases associated with excessive secretion of IL6, and transplant rejection (e.g., organ graft rejection) and proliferative diseases. |